Manila Times Business
Dioseve Secures JPY 1.45 Billion to Advance iPS Cell‑Based IVF Support, Adds TIME100 Scientist as Advisor
Funding round and NEDO Deep Tech Startup Support Program selection will support development and clinical adoption of DIOS‑101, an iPS cell‑derived co‑culture designed to reduce the burden of IVF treatment. TOKYO, June 17, 2026 /PRNewswire/ -- Dioseve Inc. ("Dioseve"), a Tokyo-based fertility biotech company developing iPS cell-derived ovarian support technologies for in vitro oocyte maturation to reduce the physical and emotional burden of IVF, today announced the completion of an extended Serie
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
A month-old pony moves to a 4th-floor apartment in Croatia. Neighbors don't mind
2h ago
Toll Brothers Announces Final Opportunity to Purchase a New Home at Regency at Caramella Ranch in South Reno, Nevada
2h ago
Toll Brothers Offers Move-in Ready Townhomes Just Minutes from Washington, D.C.
2h ago
From Watching to Creating: SoonLab Debuts AI Platform That Lets Anyone Build Soccer Games During the World Cup
2h ago